Abstract: The scope of this review is to revise recent advances of the cell-based therapies of liver diseases with an emphasis on cell donor’s and patient’s age. Regenerative medicine with cell-based technologies as its integral part is focused on the structural and functional restoration of tissues impaired by sickness or aging. Unlike drug-based medicine directed primarily at alleviation of symptoms, regenerative medicine offers a more holistic approach to disease and senescence management aimed to achieve restoration of homeostasis. Hepatocyte transplantation and organ engineering are very probable forthcoming options of liver disease treatment in people of different ages and vigorous research and technological innovations in this area are in progress. Accordingly, availability of sufficient amounts of functional human hepatocytes is crucial. Direct isolation of autologous hepatocytes from liver biopsy is problematic due to related discomfort and difficulties with further expansion of cells, particularly those derived from aging people. Allogeneic primary human hepatocytes meeting quality standards are also in short supply. Alternatively, autologous hepatocytes can be produced by reprogramming of differentiated cells through the stage of induced pluripotent stem cells. In addition, fibroblasts and mesenchymal stromal cells can be directly induced to undergo advanced stage hepatogenic differentiation. Reprogramming of cells derived from elderly people is accompanied by the reversal of age-associated changes at the cellular level manifesting itself by telomere elongation and the U-turn of DNA methylation. Cell reprogramming can provide high quality rejuvenated hepatocytes for cell therapy and liver tissue engineering. Further technological advancements and establishment of national and global registries of induced pluripotent stem cell lines homozygous for HLA haplotypes can allow industry-style production of livers for immunosuppression-free transplantation. Keywords: cell aging, rejuvenation, liver engineering, liver cell therapy
Autotransplantation of immune cells to induce immunological rejection of tumors can be a useful approach in tumor treatment. Despite the low efficiency of this approach demonstrated in the past, the active development of cell technologies and genetic engineering has led to the significant improvement in clinical outcomes. A great success was achieved in adoptive immunotherapy with the T-lymphocytes specific to tumor antigens. This review describes the clinical experience in application of various antigen-specific adoptive immunotherapy methods including tumor-infiltrating T-lymphocytes, T-lymphocytes with redirected transgenic T-cell and chimeric antigenrecognizing receptors. The possibilities and limitations of these biomedical technologies are also analyzed in the article.
Intra-arterial (IA) mesenchymal stem cells (MSCs) transplantation providing targeted cell delivery to brain tissue is a promising approach to the treatment of neurological disorders, including stroke. Factors determining cell distribution after IA administration have not been fully elucidated. Their decoding may contribute to the improvement of a transplantation technique and facilitate translation of stroke cell therapy into clinical practice. The goal of this work was to quantitatively assess the impact of brain tissue perfusion on the distribution of IA transplanted MSCs in rat brains. We performed a selective MR-perfusion study with bolus IA injection of gadolinium-based contrast agent and subsequent IA transplantation of MSCs in intact rats and rats with experimental stroke and evaluated the correlation between different perfusion parameters and cell distribution estimated by susceptibility weighted imaging (SWI) immediately after cell transplantation. The obtained results revealed a certain correlation between the distribution of IA transplanted MSCs and brain perfusion in both intact rats and rats with experimental stroke with the coefficient of determination up to 30%. It can be concluded that the distribution of MSCs after IA injection can be partially predicted based on cerebral perfusion data, but other factors requiring further investigation also have a significant impact on the fate of transplanted cells.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
'/%3e%3cpath id='b' d='M658.84 441.31c-7.618 16.446-22.845 19.271-36.164 5.995 0 0 5.354-3.783 11.086-4.826-1.075-4.574 1.13-10.902 4.235-14.324 3.258 2.227 7.804 6.689 8.96 11.874 8.03-1.04 11.883 1.282 11.883 1.282z'/%3e%3cuse xlink:href='%23b' transform='rotate(9.37 700 804)'/%3e%3cuse xlink:href='%23b' transform='rotate(18.74 700 804)'/%3e%3cpath fill='none' stroke='%23f8c300' stroke-width='16' d='M603 478a340 340 0 0 1 194 0'/%3e%3cg transform='translate(700 380)'%3e%3cg transform='translate(0 -140)'%3e%3cpath id='c' d='m0-513674 301930 929245-790463-574305h977066l-790463 574305z' transform='scale(.00005)'/%3e%3c/g%3e%3cg id='d'%3e%3cuse xlink:href='%23c' transform='translate(-70 -121.244)'/%3e%3cuse xlink:href='%23c' transform='translate(-121.244 -70)'/%3e%3cuse xlink:href='%23c' transform='translate(-140)'/%3e%3c/g%3e%3cuse xlink:href='%23d' transform='scale(-1 1)'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)